Stockscreener 앱 받기
132.39
0.72%
-0.96
전일 마감가:
$133.35
열려 있는:
$133.31
하루 거래량:
1.01M
Relative Volume:
0.97
시가총액:
$13.20B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
44.88
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-2.50%
1개월 성능:
-10.99%
6개월 성능:
-0.82%
1년 성능:
-6.72%
1일 변동 폭
$131.36
$134.02
1주일 범위
$131.30
$135.98
52주 변동 폭
$84.23
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.39 | 13.30B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR - simplywall.st
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data - simplywall.st
Neurocrine presents data showing INGREZZA achieved higher target occupancy - StreetInsider
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PR Newswire
Neurocrine Biosciences describes new GLP-1R/GIPR/GCGR agonists - BioWorld MedTech
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC - MarketBeat
With Neurocrine Biosciences, Inc. (NASDAQ:NBIX) It Looks Like You'll Get What You Pay For - 富途牛牛
Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Gap Down: Can Neurocrine Biosciences Inc be recession proofBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Price-Driven Insight from (NBIX) for Rule-Based Strategy - Stock Traders Daily
Investor Mood: What is the Moat Score of Harbor Etf Trust Smid Capital Value EtfWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Lobbying Update: $60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Peregrine Capital Management LLC Reduces Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure - Sahm
How Neurocrine Biosciences Inc. stock benefits from tech adoption2025 Short Interest & Weekly Breakout Stock Alerts - Улправда
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
Why Neurocrine Biosciences Inc. stock could be next big winnerInsider Buying & Safe Swing Trade Setups - ulpravda.ru
Entry Recap: How Neurocrine Biosciences Inc stock benefits from tech adoptionMarket Growth Summary & Long-Term Capital Growth Strategies - moha.gov.vn
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $169.00 at Truist Financial - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Equal Weight" Rating from Morgan Stanley - MarketBeat
NBIX Analyst Downgrade by Morgan Stanley with Raised Price Targe - GuruFocus
Neurocrine Bio. stock rating downgraded by Morgan Stanley on competition - Investing.com Canada
How Neurocrine Biosciences Inc. stock performs in weak economyStock Liquidity Analysis & Affordable Growth Trading - ulpravda.ru
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easingTechnical Analysis Insights & Crush the Market with Breakout Winners - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownHere's Why - MarketBeat
UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com - Investing.com Canada
Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
Allspring Global Investments Holdings LLC Has $52.39 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
13,364 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Pacer Advisors Inc. - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by Zacks Research to "Hold" - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Position Lessened by Simplify Asset Management Inc. - MarketBeat
Neurocrine Biosciences executive sells shares totaling $258,263 - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Burney Co. Has $4.05 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.75%
1.45%
자본화:
|
볼륨(24시간):